delandistrogene moxeparvovec (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

AdultPediatric

See pediatric dosing

Duchenne Muscular Dystrophy

Gene therapy pending FDA approval for ambulant individuals with Duchenne muscular dystrophy

Next:

Pharmacology

Mechanism of Action

Gene transfer therapy intended to deliver delandistrogene moxeparvovec to muscle tissue for targeted production of functional components of dystrophin

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.